Skip to main content
SpringerLink
Log in

Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Type 2 diabetes is an increasing problem in China, yet there is a paucity of data regarding the cost-effectiveness of pharmacological interventions in the Chinese setting.

Methods

Previous data were obtained from PRESENT (Physicians’ Routine Evaluation of Safety and Efficacy of NovoMix 30 Therapy), a multicountry, single-arm, observational study where type 2 diabetes patients poorly controlled with biphasic human insulin (BHI) were converted to biphasic insulin aspart 30 (BIAsp30); the Chinese subgroup experienced an improvement in HbA1c and a reduction in hypoglycaemic events. A published and validated computer simulation model of diabetes (the CORE Diabetes Model) was used to estimate the long-term clinical and cost consequences of switching to BIAsp30 from BHI in the Chinese setting. Treatment effects and patient characteristics were derived from PRESENT and countryspecific published sources. Primary research was performed to ascertain patient management practices and diabetes-related complication costs. Risks of modelled complications were derived from landmark clinical trials and epidemiological studies. Costs and clinical projections were made over patient lifetimes from a third-party payer perspective and discounted at 3% annually. Extensive sensitivity analyses were performed.

Results

Conversion to BIAsp30 from BHI was projected to improve discounted life expectancy by 0.38 years per patient (9.91 vs 9.53 years) and quality-adjusted life expectancy by 0.91 quality-adjusted life years (QALYs) per patient (6.32 vs 5.41 QALYs). Conversion to BIAsp30 was associated with increased direct medical costs of Chinese Yuan (CNY) 1751 per patient, due to higher pharmacy and management costs (CNY +19,007), offset by reduced diabetes-related complication costs (CNY −17,254) over patient lifetimes. BIAsp30 was associated with an incremental cost-effectiveness ratio of CNY 1926 per QALY gained.

Conclusion

BIAsp30 was projected to substantially improve clinical outcomes but was associated with increased lifetime medical costs. BIAsp30 would be considered cost-effective in China given a willingness-to-pay threshold of CNY 100,000 per QALY gained in type 2 diabetes patients poorly controlled on BHI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005;28:2130–2135.

    Article  PubMed  Google Scholar 

  2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053.

    Article  PubMed  Google Scholar 

  3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–1431.

    Article  PubMed  CAS  Google Scholar 

  4. International Diabetes Federation. Diabetes Atlas. 3rd edition. Brussels: International Diabetes Federation; 2007.

    Google Scholar 

  5. Popkin BM. Nutrition in transition: the changing global nutrition challenge. Asia Pac J Clin Nutr. 2001;10(suppl):S13–S18.

    PubMed  Google Scholar 

  6. Zhao W, Chen J. Implications from and for food cultures for cardiovascular disease: diet, nutrition and cardiovascular diseases in China. Asia Pac J Clin Nutr. 2001;10:146–152.

    Article  PubMed  CAS  Google Scholar 

  7. The maladies of affluence. The Economist. 9 August 2007. Available at: www.economist.com/world/international/displaystory.cfm?story_id=9616897. Accessed 2007.

  8. Jia WP, Pang C, Chen L, et al. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a crosssectional 3-year follow-up study in Shanghai urban communities. Diabetologia. 2007;50:286–292.

    Article  PubMed  CAS  Google Scholar 

  9. Dong Y, Gao W, Nan H, et al. Prevalence of type 2 diabetes in urban and rural Chinese populations in Qingdao, China. Diabet Med. 2005;22:1427–1433.

    Article  PubMed  CAS  Google Scholar 

  10. World Health Organization. Diabetes is a common condition and its frequency is dramatically rising all over the world. Available at: www.who.int/diabetes/commoncondition/en. Accessed 2008.

  11. Chan JC, Ng MC, Critchley JA, et al. Diabetes mellitus-a special medical challenge from a Chinese perspective. Diabetes Res Clin Pract. 2001;54(suppl 1):S19–S27.

    Article  PubMed  Google Scholar 

  12. Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association. Diabetes Care. 1998;21:296–309.

    Article  Google Scholar 

  13. Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia. 2002;45:S5–S12.

    Article  PubMed  CAS  Google Scholar 

  14. Chen XB, Tang L, Chen HY. Assessing the impact of complications on the costs of type 2 diabetes in urban China. Chin J Diabetes. 2003;11:238–241.

    Google Scholar 

  15. Xie X, Vondeling H. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China. Value Health. 2008;11(suppl 1):S23–S32.

    Article  PubMed  Google Scholar 

  16. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31:596–615.

    Article  Google Scholar 

  17. Vora JP, Ibrahim HA, Bakris GL. Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J Hum Hypertens. 2000;14:667–685.

    Article  PubMed  CAS  Google Scholar 

  18. Ray JA, Valentine WJ, Secnik K, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin. 2005;21:1617–1629.

    Article  PubMed  Google Scholar 

  19. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation; 2005.

    Google Scholar 

  20. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.

    Article  Google Scholar 

  21. The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.

    Article  Google Scholar 

  22. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963–1972.

    Article  PubMed  Google Scholar 

  23. Smith SA, Murad MH. Review: long-acting insulin analogues do not improve glycaemic control but reduce nocturnal hypoglycaemia. Evid Based Med. 2008;13:79.

    Article  PubMed  Google Scholar 

  24. Bolli GB, Di Marchi RD, Park GD, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 1999;42:1151–1167.

    Article  PubMed  CAS  Google Scholar 

  25. Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care. 1983;6:374–377.

    Article  PubMed  CAS  Google Scholar 

  26. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006;(19):CD003287.

  27. Shestakova M, Sharma SK, Almustafa M, et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin. 2007;23:3209–3214.

    Article  PubMed  CAS  Google Scholar 

  28. Khutsoane D, Sharma SK, Almustafa M, et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. 2008;10:212–222.

    Article  PubMed  CAS  Google Scholar 

  29. Sharma SK, Al-Mustafa M, Oh SJ, et al. Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study. Curr Med Res Opin. 2008;24:645–652.

    Article  PubMed  CAS  Google Scholar 

  30. Gao Y, Guo XH, Vaz JA, et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study. Diabetes Obes Metab. 2008; May 20. In press.

  31. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20:S5–S26.

    Article  PubMed  Google Scholar 

  32. Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20:S27–S40.

    Article  PubMed  Google Scholar 

  33. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412.

    Article  PubMed  CAS  Google Scholar 

  34. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703–713.

    Google Scholar 

  35. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–419.

    Article  PubMed  CAS  Google Scholar 

  36. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671–679.

    Article  CAS  Google Scholar 

  37. Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke. 2002;33:1776–1781.

    Article  PubMed  Google Scholar 

  38. UK Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–1258.

    Article  Google Scholar 

  39. D’Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139:272–281.

    Article  PubMed  CAS  Google Scholar 

  40. World Health Organization. Life tables for 191 countries. World mortality in 2005. Available at: www3.who.int/whosis/life_tables/life_tables.cfm 2007. Accessed 2008.

  41. World Health Organization. Global burden of disease estimates. 2004. Available at: www. who.int/healthinfo/bodestimates/en/index.html. Accessed 2008.

  42. Annemans L, Demarteau N, Hu S, et al. An Asian regional analysis of costeffectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy. Value Health. 2008;3:354–364.

    Article  Google Scholar 

  43. Lin S. Nephrology in China: a great mission and momentous challenge. Kidney Int Suppl. 2003;(83):S108–S110.

  44. Thomas GN, Critchley JA, Tomlinson B, et al. Peripheral vascular disease in type 2 diabetic Chinese patients: associations with metabolic indices, concomitant vascular disease and genetic factors. Diabet Med. 2003;20:988–995.

    Article  PubMed  CAS  Google Scholar 

  45. Xu L, Xie X, Wang S, et al. Prevalence of diabetes mellitus in China. Exp Clin Endocrinol Diabetes. 2008;116:69–70.

    Article  PubMed  CAS  Google Scholar 

  46. Valentine WJ, Palmer AJ, Nicklasson L, et al. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets. Int J Clin Pract. 2006;60:1138–1145.

    Article  PubMed  CAS  Google Scholar 

  47. Hsiao WC. The Chinese health care system: lessons for other nations. Soc Sci Med. 1995;41:1047–1055.

    Article  PubMed  CAS  Google Scholar 

  48. Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22:1523–1534.

    Article  PubMed  Google Scholar 

  49. International Society for Pharmacoeconomics and Outcomes Research. Chinese Medical Doctor Association Pharmacoeconomics Chapter. Pharmacoeconomic Guidelines. ISPOR 2005. Available at: www.pe-cn.org/en/pe_guidelines/index.asp. Accessed 2008.

  50. World Health Organization. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization; 2003.

    Google Scholar 

  51. Barzi F, Patel A, Gu D, et al. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health. 2007;61:115–121.

    Article  PubMed  CAS  Google Scholar 

  52. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997;6:327–340.

    Article  PubMed  CAS  Google Scholar 

  53. World Health Organization. Report on Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization; 2001.

    Google Scholar 

  54. Central Intelligence Agency. The 2008 World Factbook. Washington: Central Intelligence Agency; 2008.

    Google Scholar 

  55. Yuan Y, Iloeje U, Li H, et al. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health. 2008;11(suppl 1):S11–S22.

    Article  PubMed  Google Scholar 

  56. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 2001;12:2753–2758.

    PubMed  CAS  Google Scholar 

  57. Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, et al. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand. Value Health. 2008;11(suppl 1):S43–S51.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. IMS Health, Basel, Switzerland

    James L. Palmer

  2. IMS Health, Shanghai, China

    James L. Palmer & Meaghan Gibbs

  3. IMS Health, London, UK

    Huib WKFH Scheijbeler & Robert W. Kotchie

  4. Novo Nordisk A/S, Bagsværd, Denmark

    Steffen Nielsen

  5. Novo Nordisk International Operations A/S, Zurich, Switzerland

    Jeremy White

  6. IMS Health, Basel, Switzerland

    William J. Valentine

Authors
  1. James L. Palmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meaghan Gibbs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Huib WKFH Scheijbeler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert W. Kotchie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Steffen Nielsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jeremy White
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. William J. Valentine
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Palmer, J.L., Gibbs, M., Scheijbeler, H.W. et al. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Therapy 25, 752–774 (2008). https://doi.org/10.1007/s12325-008-0080-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-008-0080-4

Keywords

Search

Navigation